These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8247304)

  • 41. Influence of whole blood on standard curve for heparin measurement--possible heparin binding by red cells.
    Melissari E; Thye C; Scully MF; Kakkar VV
    Thromb Haemost; 1989 Apr; 61(2):262-5. PubMed ID: 2749600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Standardization of the activated partial thromboplastin time for monitoring of heparin therapy: where should we go?
    van den Besselaar AM
    Ric Clin Lab; 1989; 19(4):371-7. PubMed ID: 2633305
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Standardization of APTT reagents for heparin therapy monitoring: urgent or fading priority?
    Eby C
    Clin Chem; 1997 Jul; 43(7):1105-7. PubMed ID: 9216444
    [No Abstract]   [Full Text] [Related]  

  • 44. Bedside heparin monitoring by activated partial thromboplastin time measured with a dry reagent.
    Linder R; Grip L; Olason E; Blombäck M
    Clin Chem; 1996 Sep; 42(9):1488-9. PubMed ID: 8787710
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions in heparin therapy.
    Werner M; Gallagher JV; Ballo MS; Karcher DS
    Am J Clin Pathol; 1994 Aug; 102(2):237-41. PubMed ID: 8042595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Venipuncture vs. arterial catheter activated partial thromboplastin times in heparinized patients.
    Hancock RD
    Dimens Crit Care Nurs; 1993; 12(5):238-45. PubMed ID: 8243215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monitoring the intrinsic pathway of coagulation during heparin therapy.
    Hoffmann JJ
    Thromb Haemost; 1985 Feb; 53(1):161. PubMed ID: 3992518
    [No Abstract]   [Full Text] [Related]  

  • 48. Monitoring the intrinsic pathway of coagulation during heparin therapy--reply.
    Griffiths BL
    Thromb Haemost; 1985 Apr; 53(2):287. PubMed ID: 4024038
    [No Abstract]   [Full Text] [Related]  

  • 49. [Monitoring heparin therapy by the determination of blood coagulation time using kaolin].
    Uszyński L; Klukowski M
    Pol Tyg Lek; 1984 Nov; 39(46):1505-7. PubMed ID: 6514631
    [No Abstract]   [Full Text] [Related]  

  • 50. Laboratory monitoring of unfractionated heparin treatment.
    Samama MM
    Clin Lab Med; 1995 Mar; 15(1):109-17. PubMed ID: 7781273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient based ratios in the monitoring of therapeutic heparinisation by activated partial thromboplastin time.
    Cartwright K; Ip B; Crane G
    Pathology; 1997 Nov; 29(4):450. PubMed ID: 9423235
    [No Abstract]   [Full Text] [Related]  

  • 52. Heparin treatment: confusion still prevails.
    Krulder JW; Briët E
    Neth J Med; 1989 Aug; 35(1-2):1-3. PubMed ID: 2779689
    [No Abstract]   [Full Text] [Related]  

  • 53. Stability of the activated partial thromboplastin time used to monitor unfractionated heparin.
    Ray M
    J Thromb Haemost; 2008 Oct; 6(10):1817-9. PubMed ID: 18662258
    [No Abstract]   [Full Text] [Related]  

  • 54. Correlation of whole blood activated partial thromboplastin time and plasma activated partial thromboplastin time in haemodialysis patients.
    Low CL; Eisele G; Bailie GR
    Nephrol Dial Transplant; 1996 Dec; 11(12):2523. PubMed ID: 9017643
    [No Abstract]   [Full Text] [Related]  

  • 55. Heparinization schedule for PD catheter not in use.
    Bernardini J
    ANNA J; 1996 Feb; 23(1):45, 54. PubMed ID: 8702360
    [No Abstract]   [Full Text] [Related]  

  • 56. Elevated APTT? How best to follow up.
    Rehman HU
    J Fam Pract; 2013 Jun; 62(6):E1-3. PubMed ID: 23828806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring heparin therapy: problems and promise.
    Olson JD
    CAP Today; 1994 Jul; 8(7):12-3, 16. PubMed ID: 10150194
    [No Abstract]   [Full Text] [Related]  

  • 58. Comment: modification of weight-based heparin nomogram.
    Bradford GS; Taylor CT
    Ann Pharmacother; 1998 Jun; 32(6):715-6. PubMed ID: 9640493
    [No Abstract]   [Full Text] [Related]  

  • 59. Monitoring heparin therapy.
    Raschke R; Reilly B
    Ann Intern Med; 1994 Jan; 120(2):169-70. PubMed ID: 8256984
    [No Abstract]   [Full Text] [Related]  

  • 60. Monitoring heparin therapy.
    Shojania AM
    Ann Intern Med; 1994 Jan; 120(2):170. PubMed ID: 8256985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.